Immorta Bio Proposes Tech-Driven Blueprint for Precision Medicine

The research, a collaborative effort between Immorta Bio, Theriome Inc., and the American Board of Precision Medicine, outlines a framework for a continuously learning healthcare ecosystem. By integrating these four pillars, the authors aim to replace isolated biomarkers with a unified model of care. As a proof of concept, the study analyzed metabolomic data from 2,000 individuals, identifying nine specific metabolites that shift with age, suggesting a path toward real-time monitoring of biological aging.

Dr. Anil Bajnath of the American Board of Precision Medicine stated that the model provides a necessary structure for integrating secure patient data ownership with clinical decision-making. For Immorta Bio, this roadmap informs the development of its SenoVax platform. Dr. Thomas E. Ichim noted that the company is already leveraging computational biology and multi-omics to accelerate the design of senolytic peptide immunotherapies. By anchoring clinical strategy to these technologies, the collaborators believe they can address the fundamental drivers of aging while creating more precise, individualized therapeutic interventions.